search
Back to results

Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine

Primary Purpose

Lung Neoplasms

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Lidocaine
Saline
Sponsored by
RenJi Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Lung Neoplasms focused on measuring Double-lumen Endotracheal Intubation

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: aged 18-65 years, American Society of Anesthesiologists class I-II participants undergoing double-lumen endotracheal intubation under general anesthesia signed informed consent and volunteered to participate in the experiment Exclusion Criteria: Poor control of hypertension preoperative arrhythmia severe coronary artery or heart valve disease sequelae of cerebrovascular accident severe lung, liver, kidney and immune system diseases Suspected difficult airway confirmed or suspected allergy to this trial drug As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    lidocaine

    saline

    Arm Description

    Intervention group

    control group

    Outcomes

    Primary Outcome Measures

    mean arterial pressure after intubation

    Secondary Outcome Measures

    Full Information

    First Posted
    April 24, 2023
    Last Updated
    May 6, 2023
    Sponsor
    RenJi Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05850702
    Brief Title
    Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine
    Official Title
    Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine: a Randomized, Double-blind, Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 15, 2023 (Anticipated)
    Primary Completion Date
    March 9, 2025 (Anticipated)
    Study Completion Date
    September 9, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    RenJi Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this clinical trial is to test the effect of nebulized lidocaine on the hemodynamic response in the participant undergoing double-lumen endotracheal intubation. The main question it aims to answer is to evaluate the changes in mean arterial pressure after intubation. Participants will inhale 5ml of 2% lidocaine by nebulization15min before intubation. Researchers will compare saline group to see if saline effects

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lung Neoplasms
    Keywords
    Double-lumen Endotracheal Intubation

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    92 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    lidocaine
    Arm Type
    Experimental
    Arm Description
    Intervention group
    Arm Title
    saline
    Arm Type
    Placebo Comparator
    Arm Description
    control group
    Intervention Type
    Drug
    Intervention Name(s)
    Lidocaine
    Intervention Description
    inhale 5ml of 2% lidocaine by nebulization
    Intervention Type
    Drug
    Intervention Name(s)
    Saline
    Intervention Description
    inhale 5ml of saline by nebulization
    Primary Outcome Measure Information:
    Title
    mean arterial pressure after intubation
    Time Frame
    Immediately after intubation

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: aged 18-65 years, American Society of Anesthesiologists class I-II participants undergoing double-lumen endotracheal intubation under general anesthesia signed informed consent and volunteered to participate in the experiment Exclusion Criteria: Poor control of hypertension preoperative arrhythmia severe coronary artery or heart valve disease sequelae of cerebrovascular accident severe lung, liver, kidney and immune system diseases Suspected difficult airway confirmed or suspected allergy to this trial drug As judged by the investigator to be ineligible for the study, such as communication impairment (language or intelligence)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Hao Zhu
    Phone
    008602168383702
    Email
    zhuhaossmu@163.com

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine

    We'll reach out to this number within 24 hrs